<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03474055</url>
  </required_header>
  <id_info>
    <org_study_id>ROTA:06</org_study_id>
    <nct_id>NCT03474055</nct_id>
  </id_info>
  <brief_title>Study on Liquid Bovine Rotavirus Pentavalent Vaccine (LBRV-PV) to Evaluate Lot-to-Lot Consistency and to Compare Non-Inferiority With ROTASIIL (Lyophilized BRV-PV) in Healthy Infants in India</brief_title>
  <official_title>A Phase II/III, Multicenter, Open-Label, Randomized Study of Liquid Bovine Rotavirus Pentavalent Vaccine (LBRV-PV) to Evaluate Lot-to-Lot Consistency and to Compare Non-Inferiority With ROTASIIL (Lyophilized BRV-PV) in Healthy Infants in India</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Serum Institute of India Pvt. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Serum Institute of India Pvt. Ltd.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study has been designed to compare the liquid formulation of BRV-PV (LBRV-PV) with the
      lyophilized formulation (ROTASIIL) by testing the vaccine in infants (three doses
      administered 4 weeks apart, starting at 6-8 weeks of age) in order to demonstrate the
      non-inferiority in the induction of specific anti-rotavirus IgA antibodies by these vaccines.
      The study will also evaluate lot-to-lot consistency in the manufacture of LBRV-PV by
      demonstrating equivalence in the induction of specific anti-rotavirus IgA antibodies across
      three production lots.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 30, 2017</start_date>
  <completion_date type="Anticipated">September 30, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 20, 2018</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immunogenicity of rotavirus vaccine</measure>
    <time_frame>28 days post dose 3</time_frame>
    <description>Serum anti- rotavirus IgA antibody concentrations expressed as GMCs for the comparison of LBRV-PV vaccine and ROTASIIL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoints</measure>
    <time_frame>28 days post dose 3</time_frame>
    <description>GMCs of serum anti- rotavirus IgA antibody among the LBRV-PV lots at four weeks after the third vaccination.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity Endpoints</measure>
    <time_frame>28 days post dose 3</time_frame>
    <description>Proportion of subjects achieving IgA antibody concentration â‰¥20 U/ml for the comparison of LBRV-PV and ROTASIIL.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">1500</enrollment>
  <condition>Rotavirus Gastroenteritis</condition>
  <arm_group>
    <arm_group_label>LBRV-PV Lot A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot A).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LBRV-PV Lot B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot B).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>LBRV-PV Lot C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study participants in this arm will receive one of the three liquid rotavirus vaccine lots (LBRV-PV Lot C).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ROTASIIL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The study participants in this arm will receive ROTASIIL, the licensed lyophilized rotavirus vaccine in India.</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Liquid Rotavirus Vaccine</intervention_name>
    <description>Liquid Rotavirus Vaccine and Lyophilized Rotavirus Vaccine</description>
    <arm_group_label>LBRV-PV Lot A</arm_group_label>
    <arm_group_label>LBRV-PV Lot B</arm_group_label>
    <arm_group_label>LBRV-PV Lot C</arm_group_label>
    <arm_group_label>ROTASIIL</arm_group_label>
    <other_name>ROTASIIL</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Healthy infants as established by medical history and clinical examination before
             entering the study.

          2. Age: 6-8 weeks at the time of enrollment.

          3. Parental ability and willingness to provide informed consent.

          4. Parent who intends to remain in the area with the child during the study period.

        Exclusion Criteria:

          1. Presence of diarrhea or vomiting in the previous 72 hours or on the day of enrollment.

          2. Acute disease at the time of enrollment (temporary exclusion)

          3. Concurrent participation in another clinical trial at any point throughout the entire
             time frame for this study

          4. History of congenital abdominal disorders, intussusception, or abdominal surgery.

          5. Known or suspected impairment of immunological function based on medical history and
             physical examination.

          6. History of any neurologic disorders or seizures.

          7. Any medical condition in the parents / infant which, in the judgment of the
             Investigator, would interfere with or serves as a contraindication to protocol
             adherence or a participant's parents' ability to give informed consent.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Weeks</minimum_age>
    <maximum_age>8 Weeks</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Dr Prasad Kulkarni, MD</last_name>
    <phone>+91-20-26602384</phone>
    <email>drpsk@seruminstitute.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Dr Sajjad Desai, MD</last_name>
    <phone>+91-20-26602781</phone>
    <email>sajjad.desai@seruminstitute.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hakeem Abdul Hameed Centenary Hospital</name>
      <address>
        <city>New Delhi</city>
        <state>Delhi</state>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Chandra Mohan Kumar, M. D.</last_name>
      <phone>+91-9810730206</phone>
      <email>drcmkumar.himsr@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre for Vaccine Studies, Prasanna School of Public Health, Manipal University, Manipal,</name>
      <address>
        <city>Udupi</city>
        <state>Karnataka</state>
        <zip>576104</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Veena Kamath, M. D.</last_name>
      <phone>+91-820-2922324</phone>
      <email>veenak@manipal.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>KEM Hospital Research Centre</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411028</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Anand Kawde, MD</last_name>
      <email>askawade@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Bharati Vidyapeeth Medical College and Hospital, Pune</name>
      <address>
        <city>Pune</city>
        <state>Maharashtra</state>
        <zip>411043</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Sanjay Lalwani, M. D.</last_name>
      <phone>+91-20-24372789</phone>
      <email>researchpedpune@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of community Medicine, Dr Sushila Nayar School of Public Health, Mahatma Gandhi Institute of Medical Sciences, Sewagram</name>
      <address>
        <city>Wardha</city>
        <state>Maharashtra</state>
        <zip>442102</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Abhishek Raut, M.D.</last_name>
      <phone>07152284341</phone>
      <email>abhishekvraut@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sri Ramachandra Medical Centre, Chennai</name>
      <address>
        <city>Chennai</city>
        <state>Tamil Nadu</state>
        <zip>600116</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Padmasani Venkat Raman, M. D.</last_name>
      <phone>+91-44-24890002</phone>
      <email>padmasani2001@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of Child Health, Kolkata</name>
      <address>
        <city>Kolkata</city>
        <state>West Bengal</state>
        <zip>700017</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dr Ritabrata Kundu, M. D.</last_name>
      <phone>+91-33-22905626</phone>
      <email>rkundu22@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Post Graduate Institute of Medical Education and Research, Chandigarh</name>
      <address>
        <city>Chandigarh</city>
        <zip>160012</zip>
        <country>India</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Dr Madhu Gupta, M. D.</last_name>
      <phone>+91-9914208226</phone>
      <email>madhugupta21@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 11, 2018</study_first_submitted>
  <study_first_submitted_qc>March 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2018</study_first_posted>
  <last_update_submitted>April 13, 2018</last_update_submitted>
  <last_update_submitted_qc>April 13, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Liquid rotavirus vaccine</keyword>
  <keyword>LBRV-PV</keyword>
  <keyword>Gastroenteritis</keyword>
  <keyword>Diarrhoea</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gastroenteritis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vaccines</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

